Company intelligence / Profile preview

Phenotap

Ownership: Private
Development stage: Preclinical

Overview

Phenotap has developed the first non-invasive continuous ketone monitor—a sensor that delivers hourly trends of beta-hydroxybutyrate to users' smartphones. The device enables consumers to track metabolic changes and receive actionable insights to optimize diet and wellness outcomes. The product is positioned as a tool for personalized nutrition rather than treatment of specific diseases. The company participated in the UC Davis Biotech Innovation Gallery pre-accelerator program in 2024, indicating active engagement with the biotech innovation ecosystem.

Therapeutic areas: Metabolic Disorders
Modalities: Device
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Phenotap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phenotap.

Explore the full profile